Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a Post-Effective Amendment No. 3 to the Registration Statement on Form F-1 with the SEC on April 30, 2024. This filing allows for the sale of ordinary shares represented by depositary shares by certain selling shareholders. The shares may be sold on the stock market or in private transactions, and the selling shareholders may use various methods such as block trades, broker transactions, or private sales. Biodexa Pharmaceuticals has agreed to indemnify the selling shareholders against certain liabilities and will bear the costs associated with the registration of the securities. The company's shares are subject to the UK Companies Act 2006 and the City Code on Takeovers and Mergers, which may affect...Show More

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a Post-Effective Amendment No. 3 to the Registration Statement on Form F-1 with the SEC on April 30, 2024. This filing allows for the sale of ordinary shares represented by depositary shares by certain selling shareholders. The shares may be sold on the stock market or in private transactions, and the selling shareholders may use various methods such as block trades, broker transactions, or private sales. Biodexa Pharmaceuticals has agreed to indemnify the selling shareholders against certain liabilities and will bear the costs associated with the registration of the securities. The company's shares are subject to the UK Companies Act 2006 and the City Code on Takeovers and Mergers, which may affect shareholder rights and corporate control events. The depositary for the shares is JPMorgan Chase Bank, N.A., and the shares will be issued in book-entry form unless certificated shares are requested. The company has also outlined the fees and charges that shareholders will be responsible for paying in connection with the depositary shares.